New therapeutic target in primary headaches - blocking the CGRP receptor

被引:23
作者
Edvinsson, L [1 ]
机构
[1] Univ Lund Hosp, Dept Internal Med, S-22185 Lund, Sweden
关键词
calcitonin gene-related peptide (CGRP); CGRP blockers; duster headache; migraine; trigernino-vascular reflex; vasoactive intestinal peptide (VIP);
D O I
10.1517/14728222.7.3.377
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The primary headaches are among the most prevalent neurological disorders, afflicting up to 16% of the adult population. The associated pain originates from intracranial blood vessels that are innervated by sensory nerves storing several neurotransmitters. In primary headaches, there is a clear association between the headache and the release of calcitonin gene-related peptide (CGRP), but not other neuronal messengers. The specific purpose of this review is to describe CGRP in the human cranial circulation and to elucidate a possible role for a specific antagonist in the treatment of primary headaches. Acute treatment with administration of a 5-HT1B/1D agonist (triptan) results in alleviation of the headache and normalisation of the CGRP level. The mechanism of action of triptans involves vasoconstriction of intracranial vessels and a presynaptic inhibitory effect of sensory nerves. The central role of CGRP in migraine and cluster headache pathophysiology has led to the search for small-molecule CGRP antagonists, which are predicted to have fewer cardiovascular side effects in comparison to the triptans. The initial pharmacological profile of such a group of compounds has recently been disclosed. These compounds have high selectivity for human CGRP receptors and are reportedly efficacious in the relief of acute attacks of migraine.
引用
收藏
页码:377 / 383
页数:7
相关论文
共 46 条
  • [1] Aiyar N, 2001, J PHARMACOL EXP THER, V296, P768
  • [2] A cDNA encoding the calcitonin gene-related peptide type 1 receptor
    Aiyar, N
    Rand, K
    Elshourbagy, NA
    Zeng, ZZ
    Adamou, JE
    Bergsma, DJ
    Li, Y
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (19) : 11325 - 11329
  • [3] ALTERNATIVE RNA PROCESSING IN CALCITONIN GENE-EXPRESSION GENERATES MESSENGER-RNAS ENCODING DIFFERENT POLYPEPTIDE PRODUCTS
    AMARA, SG
    JONAS, V
    ROSENFELD, MG
    ONG, ES
    EVANS, RM
    [J]. NATURE, 1982, 298 (5871) : 240 - 244
  • [4] [Anonymous], CGRP FAMILY CALCITON
  • [5] Pharmacological characterization of receptor-activity-modifying proteins (RAMPs) and the human calcitonin receptor
    Armour, SL
    Foord, S
    Kenakin, T
    Chen, WJ
    [J]. JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 1999, 42 (04) : 217 - 224
  • [6] Calcitonin gene-related peptide: Vasoactive effects and potential therapeutic role
    Brain, SD
    Cambridge, H
    [J]. GENERAL PHARMACOLOGY, 1996, 27 (04): : 607 - 611
  • [7] Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product
    Christopoulos, G
    Perry, KJ
    Morfis, M
    Tilakaratne, N
    Gao, YY
    Fraser, NJ
    Main, MJ
    Foord, SM
    Sexton, PM
    [J]. MOLECULAR PHARMACOLOGY, 1999, 56 (01) : 235 - 242
  • [8] Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist
    Doods, H
    Hallermayer, G
    Wu, DM
    Entzeroth, M
    Rudolf, K
    Engel, W
    Eberlein, W
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2000, 129 (03) : 420 - 423
  • [9] RETROGRADE TRACING OF NERVE-FIBERS TO THE RAT MIDDLE CEREBRAL-ARTERY WITH TRUE BLUE - COLOCALIZATION WITH DIFFERENT PEPTIDES
    EDVINSSON, L
    HARA, H
    UDDMAN, R
    [J]. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1989, 9 (02) : 212 - 218
  • [10] Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells
    Edvinsson, L
    Alm, R
    Shaw, D
    Rutledge, RZ
    Koblan, KS
    Longmore, J
    Kane, SA
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 434 (1-2) : 49 - 53